Literature DB >> 12454801

The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.

W D Foulkes1, I Thiffault, S B Gruber, M Horwitz, N Hamel, C Lee, J Shia, A Markowitz, A Figer, E Friedman, D Farber, C M T Greenwood, J D Bonner, K Nafa, T Walsh, V Marcus, L Tomsho, J Gebert, F A Macrae, C L Gaff, B Bressac-De Paillerets, P K Gregersen, J N Weitzel, P H Gordon, E MacNamara, M-C King, H Hampel, A De La Chapelle, J Boyd, K Offit, G Rennert, G Chong, N A Ellis.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by mutations in the mismatch-repair genes. We report here the identification and characterization of a founder mutation in MSH2 in the Ashkenazi Jewish population. We identified a nucleotide substitution, MSH2*1906G-->C, which results in a substitution of proline for alanine at codon 636 in the MSH2 protein. This allele was identified in 15 unrelated Ashkenazi Jewish families with HNPCC, most of which meet the Amsterdam criteria. Genotype analysis of 18 polymorphic loci within and flanking MSH2 suggested a single origin for the mutation. All colorectal cancers tested showed microsatellite instability and absence of MSH2 protein, by immunohistochemical analysis. In an analysis of a population-based incident series of 686 Ashkenazi Jews from Israel who have colorectal cancer, we identified 3 (0.44%) mutation carriers. Persons with a family history of colorectal or endometrial cancer were more likely to carry the mutation than were those without such a family history (P=.042), and those with colorectal cancer who carried the mutation were, on average, younger than affected individuals who did not carry it (P=.033). The mutation was not detected in either 566 unaffected Ashkenazi Jews from Israel or 1,022 control individuals from New York. In hospital-based series, the 1906C allele was identified in 5/463 Ashkenazi Jews with colorectal cancer, in 2/197 with endometrial cancer, and in 0/83 with ovarian cancer. When families identified by family history and in case series are included, 25 apparently unrelated Ashkenazi Jewish families have been found to harbor this mutation. Although this pathogenic mutation is not frequent in the Ashkenazi Jewish population (accounting for 2%-3% of colorectal cancer in those whose age at diagnosis is <60 years), it is highly penetrant and accounts for approximately one-third of HNPCC in Ashkenazi Jewish families that fulfill the Amsterdam criteria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454801      PMCID: PMC420003          DOI: 10.1086/345075

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  25 in total

1.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC).

Authors:  H F Vasen; J P Mecklin; P M Khan; H T Lynch
Journal:  Dis Colon Rectum       Date:  1991-05       Impact factor: 4.585

2.  Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer.

Authors:  A L Moisio; P Sistonen; J Weissenbach; A de la Chapelle; P Peltomäki
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

Review 3.  A genetic profile of contemporary Jewish populations.

Authors:  H Ostrer
Journal:  Nat Rev Genet       Date:  2001-11       Impact factor: 53.242

4.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.

Authors:  L A Aaltonen; R Salovaara; P Kristo; F Canzian; A Hemminki; P Peltomäki; R B Chadwick; H Kääriäinen; M Eskelinen; H Järvinen; J P Mecklin; A de la Chapelle
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

5.  Founding mutations and Alu-mediated recombination in hereditary colon cancer.

Authors:  M Nyström-Lahti; P Kristo; N C Nicolaides; S Y Chang; L A Aaltonen; A L Moisio; H J Järvinen; J P Mecklin; K W Kinzler; B Vogelstein
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

6.  Phenotypic analysis of hMSH2 mutations in mouse cells carrying human chromosomes.

Authors:  G Marra; S D'Atri; H Yan; C Perrera; E Cannavo'; B Vogelstein; J Jiricny
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

7.  Complex genetic predisposition to cancer in an extended HNPCC family with an ancestral hMLH1 mutation.

Authors:  P Hutter; A Couturier; R J Scott; P Alday; C Delozier-Blanchet; F Cachat; S E Antonarakis; F Joris; M Gaudin; L D'Amato; J M Buerstedde
Journal:  J Med Genet       Date:  1996-08       Impact factor: 6.318

8.  Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques.

Authors:  C Andreutti-Zaugg; R J Scott; R Iggo
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

Review 9.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

10.  Hereditary nonpolyposis colon cancer: analysis of linkage to 2p15-16 places the COCA1 locus telomeric to D2S123 and reveals genetic heterogeneity in seven Canadian families.

Authors:  R C Green; S A Narod; J Morasse; T L Young; J Cox; G W Fitzgerald; P Tonin; O Ginsburg; S Miller; S Jothy
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

View more
  46 in total

1.  Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.

Authors:  Danielle M Friedrichsen; Janet L Stanford; Sarah D Isaacs; Marta Janer; Bao-Li Chang; Kerry Deutsch; Elizabeth Gillanders; Suzanne Kolb; Katherine E Wiley; Michael D Badzioch; S Lilly Zheng; Patrick C Walsh; Gail P Jarvik; Leroy Hood; Jeffrey M Trent; William B Isaacs; Elaine A Ostrander; Jianfeng Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

2.  Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 10q22.

Authors:  M Daniele Fallin; Virginia K Lasseter; Paula S Wolyniec; John A McGrath; Gerald Nestadt; David Valle; Kung-Yee Liang; Ann E Pulver
Journal:  Am J Hum Genet       Date:  2003-08-15       Impact factor: 11.025

3.  The New York Cancer Project: rationale, organization, design, and baseline characteristics.

Authors:  Maria K Mitchell; Peter K Gregersen; Stephen Johnson; Ramon Parsons; David Vlahov
Journal:  J Urban Health       Date:  2004-06       Impact factor: 3.671

4.  A unique MSH2 exon 8 deletion accounts for a major portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin.

Authors:  Iolanda Borelli; Marco A Barberis; Francesca Spina; Guido C Casalis Cavalchini; Caterina Vivanet; Luisa Balestrino; Monica Micheletti; Anna Allavena; Paola Sala; Carlo Carcassi; Barbara Pasini
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

5.  Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation.

Authors:  Patrizia Lastella; Margherita Patruno; Giovanna Forte; Alba Montanaro; Carmela Di Gregorio; Carlo Sabbà; Patrizia Suppressa; Adalgisa Piepoli; Anna Panza; Angelo Andriulli; Nicoletta Resta; Alessandro Stella
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

6.  Lynch Syndrome in high risk Ashkenazi Jews in Israel.

Authors:  Yael Goldberg; Inbal Kedar; Revital Kariiv; Naama Halpern; Morasha Plesser; Ayala Hubert; Luna Kaduri; Michal Sagi; Israela Lerer; Dvorah Abeliovich; Tamar Hamburger; Aviram Nissan; Hanoch Goldshmidt; Irit Solar; Ravit Geva; Hana Strul; Guy Rosner; Hagit Baris; Zohar Levi; Tamar Peretz
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

7.  Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population.

Authors:  Mef Nilbert; Friedrik P Wikman; Thomas V O Hansen; Henrik B Krarup; Torben F Orntoft; Finn C Nielsen; Lone Sunde; Anne-Marie Gerdes; Dorthe Cruger; Susanne Timshel; Marie-Louise Bisgaard; Inge Bernstein; Henrik Okkels
Journal:  Fam Cancer       Date:  2008-06-20       Impact factor: 2.375

8.  Mutation spectrum in HNPCC in the Israeli population.

Authors:  Yael Goldberg; Rinnat M Porat; Inbal Kedar; Chen Shochat; Michal Sagi; Avital Eilat; Suzan Mendelson; Tamar Hamburger; Aviram Nissan; Ayala Hubert; Luna Kadouri; Eli Pikarski; Israela Lerer; Dvorah Abeliovich; Dani Bercovich; Tamar Peretz
Journal:  Fam Cancer       Date:  2008-04-04       Impact factor: 2.375

9.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

10.  How old is this mutation? - a study of three Ashkenazi Jewish founder mutations.

Authors:  Celia M T Greenwood; Shuying Sun; Justin Veenstra; Nancy Hamel; Bethany Niell; Stephen Gruber; William D Foulkes
Journal:  BMC Genet       Date:  2010-05-14       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.